替尔泊肽与动脉粥样硬化性心血管事件风险:基于人群的队列研究
该基于人群的队列研究利用两个美国全国性理赔数据库(2022年5月至2025年5月),纳入52 971例≥40岁、2型糖尿病合并动脉粥样硬化性心血管疾病的患者,启动替尔泊肽(n=35 353)或西格列汀(n=17 618,心血管中性对照作为安慰剂替代),经倾向评分重叠加权后基线均衡。主要终点MACE(心肌梗死、卒中、全因死亡复合)1年加权风险替尔泊肽组2.9% vs 西格列汀组4.4%(风险差-1.4%,95%CI -2.1%至-0.7%;NNT=70),HR 0.68(95%CI 0.58-0.80)。心肌梗死HR 0.67(0.52-0.87;NNT=130),缺血性卒中无显著差异(HR 0.91,0.64-1.28;NNT 2500)。感染相关住院(HR 0.64,NNT=48)、感染相关死亡(HR 0.40,NNT=200)及全因死亡(HR 0.55,NNT=122)均降低,阴性对照结局无关联。
要点
- 在2型糖尿病合并 established ASCVD 患者中,启动替尔泊肽1年MACE加权风险2.9%,西格列汀组4.4%,风险差-1.4%(95%CI -2.1%至-0.7%),NNT=70。
- 心肌梗死风险降低(HR 0.67,95%CI 0.52-0.87;NNT=130),但缺血性卒中无显著差异(HR 0.91,95%CI 0.64-1.28;NNT 2500)。
- 感染需住院风险降低(HR 0.64,95%CI 0.55-0.75;NNT=48),感染相关死亡降低(HR 0.40,95%CI 0.26-0.61;NNT=200)。
- 全因死亡风险降低(HR 0.55,95%CI 0.42-0.72;NNT=122),阴性对照结局(腰椎神经根病、腹壁疝)无关联,提示残余混杂较小。
适用人群与场景
- ≥40岁、2型糖尿病合并已确诊动脉粥样硬化性心血管疾病、启动替尔泊肽(n=35 353)或西格列汀(n=17 618)治疗的美国商业保险理赔人群,数据来自两个全国性数据库(2022年5月至2025年5月)。
- 随访从治疗启动次日开始,至结局发生、退保、停药或换药、或满1年为止。
诊断标准与关键阈值
- 主要终点MACE为心肌梗死、卒中和全因死亡的复合终点,并分析各独立组分。
- 安全性终点包括需住院的感染和感染相关死亡;阴性对照结局为腰椎神经根病和腹壁疝。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:基于人群的队列研究,采用此前经随机试验基准化的设计、数据和分析方法;两个美国全国性理赔数据库;样本量52 971例(替尔泊肽35 353例,西格列汀17 618例)。
- 主要终点:1年加权MACE风险替尔泊肽组2.9%(95%CI 2.5%-3.4%),西格列汀组4.4%(95%CI 3.8%-4.9%);风险差-1.4%(95%CI -2.1%至-0.7%),NNT=70;HR 0.68(95%CI 0.58-0.80)。
- 次要终点:心肌梗死HR 0.67(95%CI 0.52-0.87;NNT=130);缺血性卒中HR 0.91(95%CI 0.64-1.28;NNT 2500);需住院感染HR 0.64(95%CI 0.55-0.75;NNT=48);感染相关死亡HR 0.40(95%CI 0.26-0.61;NNT=200);全因死亡HR 0.55(95%CI 0.42-0.72;NNT=122)。
- 阴性对照结局(腰椎神经根病、腹壁疝)未见关联。
证据类型、等级与局限
- 证据类型:基于人群的队列研究(非随机对照试验),采用经随机试验基准化的设计、数据和分析方法;原文未给出正式证据等级或推荐强度。
- 局限性:观察性设计,尽管采用倾向评分重叠加权和阴性对照结局,仍可能存在残余混杂;数据来自美国理赔数据库,结论外推需谨慎;随访上限为1年。
对床旁实践的改变
- 对于2型糖尿病合并已确诊动脉粥样硬化性心血管疾病的患者,在标准治疗基础上启动替尔泊肽可能降低1年MACE风险(风险差-1.4%,NNT=70),尤其是心肌梗死和全因死亡风险。
- 该研究提示替尔泊肽可能降低需住院感染和感染相关死亡风险,但机制尚需前瞻性验证。
- 该研究为观察性队列,不能替代随机对照试验;临床决策时应结合患者个体情况、药物可及性和指南推荐,并注意1年随访时限。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To estimate the magnitude of reduction in major adverse cardiovascular events (MACE) that would be observed in clinical practice from adding tirzepatide to standard of care treatment.
DESIGN: Population based cohort study, using a design, data, and analytical approach previously benchmarked against randomised trials.
SETTING: Two national US claims databases, May 2022 to May 2025.
PARTICIPANTS: 52 971 participants aged ≥40 years with type 2 diabetes and established atherosclerotic cardiovascular disease who initiated tirzepatide (n=35 353) or sitagliptin (n=17 618), a cardiovascular outcome neutral comparator serving as a placebo proxy. Baseline characteristics were well balanced between treatment groups after propensity score overlap weighting.
MAIN OUTCOME MEASURES: The main outcome, MACE, was a composite of myocardial infarction, stroke, and all cause mortality and its individual components. Follow-up started the day after treatment initiation and continued until occurrence of the outcome, disenrollment from the health plan, treatment discontinuation or switching, or one year. Safety outcomes included infections requiring hospital admission and infection related mortality. Two negative control outcomes, lumbar radiculopathy and abdominal hernia, were analysed to assess residual confounding.
RESULTS: At one year, the weighted one year risk of MACE was 2.9% (95% confidence interval (CI) 2.5% to 3.4%) in the tirzepatide group and 4.4% (3.8% to 4.9%) in the sitagliptin group (risk difference -1.4%, 95% CI -2.1% to -0.7%; number needed to treat (NNT)=70), corresponding to a hazard ratio of 0.68 (95% CI 0.58 to 0.80). For individual MACE components, tirzepatide was associated with a lower hazard for myocardial infarction (hazard ratio 0.67, 0.52 to 0.87; NNT=130), whereas ischaemic stroke showed no meaningful difference (0.91, 0.64 to 1.28; NNT 2500). Infections requiring hospital admission were lower with tirzepatide (0.64, 0.55 to 0.75; NNT=48), as was infection related mortality (0.40, 0.26 to 0.61; NNT=200) and all cause mortality (0.55, 0.42 to 0.72; NNT=122). Negative control outcomes showed no association.
CONCLUSIONS: In this cohort study using an approach benchmarked against randomised trials, initiating tirzepatide reduced the risk of MACE compared with a placebo proxy among people with type 2 diabetes and established atherosclerotic cardiovascular disease. Reductions in infection related events suggest broader non-atherosclerotic biological mechanisms may contribute to the observed benefit. This study shows how trial-anchored evidence from clinical practice can estimate the expected cardiovascular benefit of initiating tirzepatide beyond standard background treatment and inform shared decision making.
TRIAL REGISTRATION: ClinicalTrials.gov NCT07203677.
参考来源
- Krüger N, Schneeweiss S, Wang SV, et al. Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study. BMJ. 2026. PMID: 42556854. doi:10.1136/bmj-2026-100011
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。